Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company, announced that CEO Kimberly Blackwell will participate in two significant investor conferences. The first event is the Guggenheim Healthcare Talks | Oncology Day, scheduled for February 8, 2023, at 9:00 a.m. ET in New York City. The second event is the SVB Securities Global Biopharma Conference, taking place virtually on February 14, 2023, at 3:00 p.m. ET. Webcasts of these presentations will be available on Zentalis' website, along with archived versions post-event. Zentalis focuses on developing small molecule therapeutics for cancer treatment.

NEW YORK and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming investor conferences.

Presentation Details:

Event: Guggenheim Healthcare Talks | Oncology Day
Date/Time: Wednesday, February 8th, 2023 at 9:00 a.m. ET
Location: New York City

Event: SVB Securities Global Biopharma Conference
Date/Time: Tuesday, February 14th, 2023 at 3:00 p.m. ET
Location: Virtual

Webcasts will be accessible through the Investors section of the Company’s website at www.zentalis.com. Following the events, archived webcasts will be available on the Zentalis website.

About Zentalis Pharmaceuticals
Zentalis™ Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Utilizing its Integrated Discovery Engine, the Company is developing a focused pipeline of potentially best-in-class oncology candidates, which include azenosertib (ZN-c3), a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders, and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. The Company is also leveraging its extensive experience and capabilities across cancer biology and medicinal chemistry to advance its research on protein degraders. Zentalis has operations in both New York and San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

Investor Contacts:

Adam D. Levy, PhD, MBA
Senior Vice President, Investor Relations
alevy@zentalis.com

Alexandra Roy
Solebury Strategic Communications
aroy@soleburystrat.com

Media Contact:

Julia Deutsch
Solebury Strategic Communications
jdeutsch@soleburystrat.com

FAQ

What is Zentalis Pharmaceuticals' stock symbol?

Zentalis Pharmaceuticals' stock symbol is ZNTL.

When is Zentalis Pharmaceuticals presenting at the Guggenheim Healthcare Talks?

Zentalis Pharmaceuticals will present at the Guggenheim Healthcare Talks on February 8, 2023, at 9:00 a.m. ET.

What date is the SVB Securities Global Biopharma Conference?

The SVB Securities Global Biopharma Conference is on February 14, 2023, at 3:00 p.m. ET.

How can I access the webcasts of Zentalis Pharmaceuticals' presentations?

Webcasts of Zentalis Pharmaceuticals' presentations will be accessible through the Investors section of their website.

What is the focus of Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals focuses on discovering and developing small molecule therapeutics targeting cancer.